Former Director Of Indofarma Charged With State Loss Of IDR 377.49 Billion

The trial of reading the indictment of the alleged corruption case in the financial management of PT Indofarma Tbk. at the Jakarta Corruption Court, Monday (17/3/2025). (ANTARA/Agatha Olivia Victoria)

JAKARTA - President Director of PT Indofarma Tbk. for the 2019-2023 period, Arief Pramuhanto was charged with causing state financial losses of Rp. 377.49 billion related to the alleged corruption case of Indofarma's financial management in 2020-2023.

The Public Prosecutor (JPU) of the Attorney General's Office (Kejagung), Lenny Sebayang, said that the state's losses were caused because Arief together with other parties had enriched themselves, others, or a corporation.

"The state's finances occurred to Indofarma and its subsidiaries over financial management of Indofarma, its subsidiaries, and other relevant agencies," said the Public Prosecutor in a hearing reading the indictment at the Jakarta Corruption Court (Tipikor), Monday, March 17.

In the same trial, there was also the Finance and Accounting Manager of PT Indofarma 2020 Bayu Pratama Erdhiansyah, Director of PT Indofarma Global Medika (IGM) for the period 2020-2023 Gigik Sugiyo Raharjo, and Finance Manager of PT IGM for the period 2020-2023 Cecep Setiana Yusuf, who read out his indictment together with Arief.

The prosecutor detailed that several parties were enriched for the corruption, namely the producer of Hong Kong medical devices, SWS (HK) Ltd. amounting to Rp12.39 billion for the expenditure of Indofarma funds for the payment of raw materials for masks and finished masks.

Then, enriching Arief together with Gigik, Cecep, and Bayu overpayment for overpayments in payment transactions for TeleCTG products to PT ZTI amounting to Rp4.5 billion and enriching the four of them by Rp. 18 billion overpayment for an advance purchase of PPE hazmat to PT Mitra Medika Utama (MMU).

Corruption was also carried out to enrich the four defendants Rp24.35 billion for the wrong transfer to PT Indogenesis Medika amounting to Rp13 billion, PT Harmoni Nasional Teknologi Indonesia (PT HNTI) amounting to Rp3 billion, and PT MMU amounting to Rp8.35 billion and enriching the four from business unit expenditure transactions. Fast Moving Consumer Good (FMCG) and PT IGM of Rp135.29 billion.

Furthermore, enriching the Nusantara Cooperative on the disbursement of futures deposits worth Rp35 billion, which came from the expenditure of PT IGM funds in the form of time deposits and PT Promedik amounting to Rp12.03 billion for the disbursement of PT IGM Deposito as a credit guarantee for PT Promedik at Bank OK!, which was used to pay PT Promedik's debt to PT IGM and PT Promedik's operations.

This case also enriched PT Promedik in the amount of Rp1.53 billion for the payment of interest on PT Promedik loans at Bank OK! and SWS (Hk) Ltd of Rp6.42 billion for the remaining supply of raw materials for the unproduced INAMAsk Mask and PT Promedik of Rp56.68 billion for PT IGM's bad debt from selling Panbio rapid test products to PT Promedik.

Then enriching PT Promedik amounting to Rp68.25 billion for PT IGM's receivables from the sale of the Panbio rapid test to PT Promedik which was lost because it was made as if it was paid off using funds from Bank OK credit facilities! and PT CTI loans and enriching the four defendants Rp1.65 billion, which came from marketing costs for TeleCTG products that were not received by PT IGM and amounted to Rp1.39 billion for future savings services in Nusantara Cooperatives which were not handed over to PT IGM.